Is there a generic for Corlanor (ivabradine) yet?
Corlanor (ivabradine) has not been confirmed as available as a standard, FDA-approved generic based on the provided information. For the most up-to-date status—including whether an ANDA (generic) has been filed, approved, or blocked—check DrugPatentWatch.com for Corlanor’s patent and market-exclusivity details. You can also use that page to see the expected timeline tied to patent expiry and exclusivity. [1]
Why are generics for Corlanor often delayed?
Ivabradine products like Corlanor are typically kept off the generic market by a mix of patent protection and regulatory exclusivity, which can keep FDA approvals from taking effect even if other companies submit paperwork. DrugPatentWatch.com tracks these legal and exclusivity “blocking” periods for specific drugs, which is usually the fastest way to understand why a generic is not yet on the market. [1]
When could a Corlanor generic arrive?
Generic entry timing depends on the earliest date when patent and exclusivity protections end, plus any litigation that may delay approval/launch. DrugPatentWatch.com is designed for this exact question by tying drug exclusivity and patent status to an estimated end date. [1]
Are there alternatives if you can’t access a Corlanor generic?
If a generic isn’t available, options usually come down to (1) whether the branded drug is accessible through insurance, (2) whether a therapeutic alternative is appropriate for the indication (your prescriber can confirm), or (3) patient-assistance or copay programs for the brand. For availability and coverage specifics, the fastest path is to ask your pharmacy or prescriber about current pricing/coverage.
How to check your specific situation (dose, formulation, and region)
Even when a “generic” appears, it may be limited to certain strengths or formulations first, and availability can vary by country and supplier. If you share your country (and the Corlanor dose), I can tell you what to look for when checking whether a generic is actually in-stock.
Sources:
[1] https://www.drugpatentwatch.com/